Potential synergy between tau aggregation inhibitors and tau chaperone modulators

Alzheimer's Research and Therapy

Volumn 5, Issue 5, 2013, Pages

  Blair, Laura J ^a   Zhang, Bo ^a   Dickey, Chad A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Aggregation; Blood brain barrier; Chaperones; Heat shock proteins; Hsp70; Hsp90; Inhibitors; Tau; Tauopathies

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; B 1C 11; B 4A 1; B 4D 3; B 4D 5; CHAPERONE; CURCUMIN; DAUNORUBICIN; EMODIN; EPALRESTAT; GELDANAMYCIN; HYDROXYTYROSOL; METHYLENE BLUE; MITOXANTRONE; MYRICETIN; N 744; NOVOBIOCIN; OLEUROPEIN; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PIXANTRONE; PR 619; QUERCETIN; QUINOXALINE DERIVATIVE; RADICICOL; TANESPIMYCIN; TAU PROTEIN; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WITHAFERIN A; YM 01; YM 08;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LEARNING DISORDER; LONG TERM POTENTIATION; MEMBRANE PERMEABILITY; MICROTUBULE; MICROTUBULE ORGANIZING CENTER; NONHUMAN; PHASE 3 CLINICAL TRIAL; PLEIOTROPY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TETRATRICOPEPTIDE REPEAT;

EID: 84887973794     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt207     Document Type: Review

References (72)

1. The genetics of neurodegenerative diseases. Hardy J, Orr H, J Neurochem 2006 97 1690 1699 10.1111/j.1471-4159.2006.03979.x 16805777 (Pubitemid 43873661)
2. Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. Abisambra JF, Blair LJ, Hill SE, Jones J, Kraft C, Rogers J, Koren J, Jinwal UK, Lawson LY, Johnson AG, Wilcock D, O'Leary JC, Jansen-West K, Muschol M, Golde TE, Weeber EJ, Banko J, Dickey CA, J Neurosci 2010 30 15374 15382 10.1523/JNEUROSCI.3155-10.2010 21084594
3. Hsp70 alters tau function and aggregation in an isoform specific manner. Voss K, Combs B, Patterson KR, Binder LI, Gamblin TC, Biochemistry 2012 51 888 898 10.1021/bi2018078 22236337
4. Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. Thompson AD, Scaglione KM, Prensner J, Gillies AT, Chinnaiyan A, Paulson HL, Jinwal UK, Dickey CA, Gestwicki JE, ACS Chem Biol 2012 7 1677 1686 10.1021/cb3002599 22769591
5. Oleuropein and derivatives from olives as Tau aggregation inhibitors. Daccache A, Lion C, Sibille N, Gerard M, Slomianny C, Lippens G, Cotelle P, Neurochem Int 2011 58 700 707 10.1016/j.neuint.2011.02.010 21333710
6. Structure-activity relationship of cyanine tau aggregation inhibitors. Chang E, Congdon EE, Honson NS, Duff KE, Kuret J, J Med Chem 2009 52 3539 3547 10.1021/jm900116d 19432420
7. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM, J Biol Chem 2006 281 1205 1214 16246844
8. Development of tau aggregation inhibitors for Alzheimer's disease. Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E, Angew Chem 2009 48 1740 1752 10.1002/anie.200802621 19189357
9. Macrocyclic beta-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide. Zheng J, Liu C, Sawaya MR, Vadla B, Khan S, Woods RJ, Eisenberg D, Goux WJ, Nowick JS, J Am Chem Soc 2011 133 3144 3157 10.1021/ja110545h 21319744
10. Imbalance of Hsp70 family variants fosters tau accumulation. Jinwal UK, Akoury E, Abisambra JF, O'Leary JC, Thompson AD, Blair LJ, Jin Y, Bacon J, Nordhues BA, Cockman M, Zhang J, Li P, Zhang B, Borysov S, Uversky VN, Biernat J, Mandelkow E, Gestwicki JE, Zweckstetter M, Dickey CA, FASEB J 2013 27 1450 1459 10.1096/fj.12-220889 23271055
11. A neuronal antigen in the brains of Alzheimer patients. Wolozin BL, Pruchnicki A, Dickson DW, Davies P, Science 1986 232 648 650 10.1126/science.3083509 3083509 (Pubitemid 16061977)
12. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Wood JG, Mirra SS, Pollock NJ, Binder LI, Proc Natl Acad Sci U S A 1986 83 4040 4043 10.1073/pnas.83.11.4040 2424015 (Pubitemid 16062418)
13. Chaperone-mediated autophagy in aging and disease. Massey AC, Zhang C, Cuervo AM, Curr Top Dev Biol 2006 73 205 235 16782460 (Pubitemid 43878134)
14. Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L, Lee D, Dickson D, de Silva R, Binder LI, Morgan D, Lewis J, Am J Pathol 2009 174 228 238 10.2353/ajpath.2009.080764 19074615
15. Chaperones increase association of tau protein with microtubules. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H, Proc Natl Acad Sci U S A 2003 100 721 726 10.1073/pnas.242720499 12522269 (Pubitemid 36126119)
16. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. Shimura H, Miura-Shimura Y, Kosik KS, J Biol Chem 2004 279 17957 17962 10.1074/jbc.M400351200 14963027 (Pubitemid 38560564)
17. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS Jr, Hutton M, Burrows F, Petrucelli L, J Clin Invest 2007 117 648 658 10.1172/JCI29715 17304350 (Pubitemid 46348523)
18. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G, Proc Natl Acad Sci U S A 2007 104 9511 9516 10.1073/pnas.0701055104 17517623 (Pubitemid 47185810)
19. Hsp70 ATPase modulators as therapeutics for Alzheimer's and other neurodegenerative diseases. Jinwal UK, Koren J, O'Leary JC, Jones JR, Abisambra JF, Dickey CA, Mol Cell Pharmacol 2010 2 43 46 20523917
20. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. Miyata Y, Li X, Lee H-F, Jinwal UK, Srinivasan SR, Seguin SP, Young ZT, Brodsky JL, Dickey CA, Sun D, Gestwicki JE, ACS Chem Neurosci 2013 4 930 939 10.1021/cn300210g 23472668
21. Hsp90 modulation for the treatment of Alzheimer's disease. Zhao H, Michaelis ML, Blagg BS, Adv Pharmacol 2012 64 1 25 22840743
22. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M, Hum Mol Genet 2004 13 703 714 10.1093/hmg/ddh083 14962978 (Pubitemid 38455958)
23. Intracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of proteasome. Opattova A, Filipcik P, Cente M, Novak M, J Alzheimers Dis 2013 33 339 348 22936006
24. Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism. Dou F, Yuan LD, Zhu JJ, Acta Biochim Biophys Sin 2005 37 501 505 10.1111/j.1745-7270.2005.00069.x 15999212 (Pubitemid 41453486)
25. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO, J Biol Chem 1997 272 23843 23850 10.1074/jbc.272.38.23843 9295332 (Pubitemid 27410964)
26. A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Ansar S, Burlison JA, Hadden MK, Yu XM, Desino KE, Bean J, Neckers L, Audus KL, Michaelis ML, Blagg BS, Bioorg Med Chem Lett 2007 17 1984 1990 10.1016/j.bmcl.2007.01.017 17276679 (Pubitemid 46367655)
27. Akt and CHIP coregulate tau degradation through coordinated interactions. Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, Bailey RM, Dunmore J, Soresh S, Leon C, Morgan D, Petrucelli L, Proc Natl Acad Sci U S A 2008 105 3622 3627 10.1073/pnas. 0709180105 18292230 (Pubitemid 351723602)
28. Low endogenous and chemical induced heat shock protein induction in a 0N3Rtau-expressing Drosophila larval model of Alzheimer's disease. Sinadinos C, Quraishe S, Sealey M, Samson PB, Mudher A, Wyttenbach A, J Alzheimers Dis 2013 33 1117 1133 23114515
29. Development of radicicol analogues. Soga S, Shiotsu Y, Akinaga S, Sharma SV, Curr Cancer Drug Targets 2003 3 359 369 10.2174/1568009033481859 14529387 (Pubitemid 37128322)
30. Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. Li C, Ma J, Zhao H, Blagg BS, Dobrowsky RT, ASN Neuro 2012 4 00102 23240583
31. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line. Lu Y, Ansar S, Michaelis ML, Blagg BS, Bioorg Med Chem 2009 17 1709 1715 10.1016/j.bmc.2008.12.047 19138859
32. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. Jinwal UK, Koren J 3rd, Borysov SI, Schmid AB, Abisambra JF, Blair LJ, Johnson AG, Jones JR, Shults CL, O'Leary JC 3rd, Jin Y, Buchner J, Cox MB, Dickey CA, J Neurosci 2010 30 591 599 10.1523/JNEUROSCI.4815-09.2010 20071522
33. Chemical manipulation of hsp70 ATPase activity regulates tau stability. Jinwal UK, Miyata Y, Koren J 3rd, Jones JR, Trotter JH, Chang L, O'Leary J, Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ, Zuiderweg ER, Gestwicki JE, Dickey CA, J Neurosci 2009 29 12079 12088 10.1523/JNEUROSCI.3345-09.2009 19793966
34. Identification of small molecules that modify the protein folding activity of heat shock protein 70. Wisen S, Gestwicki JE, Anal Biochem 2008 374 371 377 10.1016/j.ab.2007.12.009 18191466
35. Allostery in the Hsp70 chaperone proteins. Zuiderweg ER, Bertelsen EB, Rousaki A, Mayer MP, Gestwicki JE, Ahmad A, Top Curr Chem 2013 328 99 153 22576356
36. Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Abisambra J, Jinwal UK, Miyata Y, Rogers J, Blair L, Li X, Seguin SP, Wang L, Jin Y, Bacon J, Brady S, Cockman M, Guidi C, Zhang J, Koren J, Young ZT, Atkins CA, Zhang B, Lawson LY, Weeber EJ, Brodsky JL, Gestwicki JE, Dickey CA, Biol Psychiatry 2013 74 367 374 10.1016/j.biopsych.2013.02.027 23607970
37. Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Akoury E, Pickhardt M, Gajda M, Biernat J, Mandelkow E, Zweckstetter M, Angew Chem 2013 52 3511 3515 10.1002/anie.201208290 23401175
38. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Bulic B, Pickhardt M, Khlistunova I, Biernat J, Mandelkow EM, Mandelkow E, Waldmann H, Angew Chem 2007 46 9215 9219 10.1002/anie.200704051 17985339 (Pubitemid 350292144)
39. Tau protein and tau aggregation inhibitors. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E, Neuropharmacology 2010 59 276 289 10.1016/j.neuropharm.2010.01.016 20149808
40. Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity. Lu J, Wu DM, Zheng YL, Hu B, Zhang ZF, Shan Q, Zheng ZH, Liu CM, Wang YJ, J Pathol 2010 222 199 212 10.1002/path.2754 20690163
41. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease? Narlawar R, Pickhardt M, Leuchtenberger S, Baumann K, Krause S, Dyrks T, Weggen S, Mandelkow E, Schmidt B, ChemMedChem 2008 3 165 172 10.1002/cmdc.200700218 17943713
42. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM, J Neurosci 2009 29 9078 9089 10.1523/JNEUROSCI.1071-09.2009 19605645
43. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA, J Biol Chem 2013 288 4056 4065 10.1074/jbc.M112.393751 23264626
44. 'Lest we forget you-methylene blue. Schirmer RH, Adler H, Pickhardt M, Mandelkow E, Neurobiol Aging 2011 32 2325 7 e16 21803453
45. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR, Proc Natl Acad Sci U S A 1996 93 11213 11218 10.1073/pnas.93.20.11213 8855335 (Pubitemid 26333144)
46. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. O'Leary JC 3rd, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, Jinwal UK, Koren J 3rd, Jones JR, Kraft C, Peters M, Abisambra JF, Duff KE, Weeber EJ, Gestwicki JE, Dickey CA, Mol Neurodegener 2010 5 45 10.1186/1750-1326-5-45 21040568
47. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, Gestwicki JE, Dickey CA, Yu WH, Duff KE, Autophagy 2012 8 609 622 10.4161/auto.19048 22361619
48. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Brunden KR, Trojanowski JQ, Lee VM, Nat Rev Drug Discov 2009 8 783 793 10.1038/nrd2959 19794442
49. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Fatouros C, Pir GJ, Biernat J, Koushika SP, Mandelkow E, Mandelkow EM, Schmidt E, Baumeister R, Hum Mol Genet 2012 21 3587 3603 10.1093/hmg/dds190 22611162
50. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. Wischik C, Staff R, J Nutr Health Aging 2009 13 367 369 10.1007/s12603-009-0046-5 19300883
51. Safety and efficacy study evaluating TRx0237 in subjects with mild to moderate alzheimer's disease http://www.clinicaltrials.gov/ct2/show/NCT01689246? term=alzheimer%27s&rank=10 20200346
52. Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies. Miyata Y, Koren J, Kiray J, Dickey CA, Gestwicki JE, Future Med Chem 2011 3 1523 1537 10.4155/fmc.11.88 21882945
53. Allosteric drugs: the interaction of antitumor compound MKT-077 with human Hsp70 chaperones. Rousaki A, Miyata Y, Jinwal UK, Dickey CA, Gestwicki JE, Zuiderweg ER, J Mol Biol 2011 411 614 632 10.1016/j.jmb.2011.06.003 21708173
54. Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance. Koren J 3rd, Miyata Y, Kiray J, O'Leary JC 3rd, Nguyen L, Guo J, Blair LJ, Li X, Jinwal UK, Cheng JQ, Gestwicki JE, Dickey CA, PLoS One 2012 7 35566 10.1371/journal.pone.0035566 22563386
55. Self-association of a small heat shock protein. Lelj-Garolla B, Mauk AG, J Mol Biol 2005 345 631 642 10.1016/j.jmb.2004.10.056 15581903 (Pubitemid 39575929)
56. Mechanism of chaperone function in small heat-shock proteins. Phosphorylation-induced activation of two-mode binding in alphaB-crystallin. Koteiche HA, McHaourab HS, J Biol Chem 2003 278 10361 10367 10.1074/jbc. M211851200 12529319 (Pubitemid 36800299)
57. Heat shock proteins and amateur chaperones in amyloid-beta accumulation and clearance in Alzheimer's disease. Wilhelmus MM, de Waal RM, Verbeek MM, Mol Neurobiol 2007 35 203 216 10.1007/s12035-007-0029-7 17917109 (Pubitemid 350129682)
58. Inhibition of alpha-synuclein aggregation by small heat shock proteins. Bruinsma IB, Bruggink KA, Kinast K, Versleijen AA, Segers-Nolten IM, Subramaniam V, Bea Kuiperij H, Boelens W, de Waal RM, Verbeek MM, Proteins 2011 79 2956 2967 10.1002/prot.23152 21905118
59. Anthraquinone-2-sulfonic acid (AQ2S) is a novel neurotherapeutic agent. Jackson TC, Verrier JD, Kochanek PM, Cell Death Dis 2013 4 451 10.1038/cddis.2012.187 23303125
60. N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Pickhardt M, Biernat J, Khlistunova I, Wang YP, Gazova Z, Mandelkow EM, Mandelkow E, Curr Alzheimer Res 2007 4 397 402 10.2174/156720507781788765 17908042 (Pubitemid 47416632)
61. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E, J Biol Chem 2005 280 3628 3635 15525637 (Pubitemid 40223830)
62. 9,10-Anthraquinone hinders beta-aggregation: how does a small molecule interfere with Abeta-peptide amyloid fibrillation? Convertino M, Pellarin R, Catto M, Carotti A, Caflisch A, Protein Sci 2009 18 792 800 19309732
63. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Pickhardt M, Larbig G, Khlistunova I, Coksezen A, Meyer B, Mandelkow EM, Schmidt B, Mandelkow E, Biochemistry 2007 46 10016 10023 10.1021/bi700878g 17685560 (Pubitemid 47378592)
64. Hydroxytyrosol administration enhances atherosclerotic lesion development in apo E deficient mice. Acin S, Navarro MA, Arbones-Mainar JM, Guillen N, Sarria AJ, Carnicer R, Surra JC, Orman I, Segovia JC, Torre Rde L, Covas MI, Fernández-Bolaños J, Ruiz-Gutiérrez V, Osada J, J Biochem 2006 140 383 391 10.1093/jb/mvj166 16873395 (Pubitemid 44703156)
65. Structure-activity relationship of cyclic thiacarbocyanine tau aggregation inhibitors. Schafer KN, Murale DP, Kim K, Cisek K, Kuret J, Churchill DG, Bioorg Med Chem Lett 2011 21 3273 3276 10.1016/j.bmcl.2011.04.039 21549596
66. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Necula M, Chirita CN, Kuret J, Biochemistry 2005 44 10227 10237 10.1021/bi050387o 16042400 (Pubitemid 41076818)
67. Potency of a tau fibrillization inhibitor is influenced by its aggregation state. Congdon EE, Necula M, Blackstone RD, Kuret J, Arch Biochem Biophys 2007 465 127 135 10.1016/j.abb.2007.05.004 17559794 (Pubitemid 47283987)
68. Inhibition of tau polymerization with a cyanine dye in two distinct model systems. Congdon EE, Figueroa YH, Wang L, Toneva G, Chang E, Kuret J, Conrad C, Duff KE, J Biol Chem 2009 284 20830 20839 10.1074/jbc.M109.016089 19478088
69. The small molecule inhibitor PR-619 of deubiquitinating enzymes affects the microtubule network and causes protein aggregate formation in neural cells: implications for neurodegenerative diseases. Seiberlich V, Goldbaum O, Zhukareva V, Richter-Landsberg C, Biochim Biophys Acta 1823 2012 2057 2068 22565157
70. The distribution of tau in the mammalian central nervous system. Binder LI, Frankfurter A, Rebhun LI, J Cell Biol 1985 101 1371 1378 10.1083/jcb.101.4.1371 3930508 (Pubitemid 16203754)
71. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM, Proc Natl Acad Sci U S A 2007 104 10252 10257 10.1073/pnas.0703676104 17535890 (Pubitemid 47175295)
72. Development of novel Zn§ssup§2+§esup§ loaded nanoparticles designed for cell-type targeted drug release in CNS neurons: in vitro evidences. Grabrucker AM, Garner CC, Boeckers TM, Bondioli L, Ruozi B, Forni F, Vandelli MA, Tosi G, PLoS One 2011 6 17851 10.1371/journal.pone.0017851 21448455